Method and system for acquiring spectral data for use in assessing risk of breast cancer
A method and system enabling a determination of the risk of developing breast cancer of a subject, comprises using a magnetic resonance spectroscopy device to obtain the level of the spectral signal at 3.15 and 3.19 ppm, within the breast tissue of the subject, and comparing the level of the spectral signal obtained in the first step with a reference level of a spectral signal at 3.15 and 3.19 ppm of the breast of a healthy subject, to determine whether the level of the signal obtained in the first step exceeds the reference level of a healthy subject is comparable to that of a subject known to be at elevated risk; or is elevated to the level of persons known to be carrying a gene mutation.
1 . A method enabling a determination of a risk of developing breast cancer of a subject by in vivo acquisition of spectral data of a breast of the subject, comprising:
a. using a magnetic resonance spectroscopy device to obtain a level of a spectral signal at 3.15 and 3.19 ppm (parts per million), within a breast tissue of the subject in vivo, and
b. comparing (i) the level of the spectral signal obtained in step a. with (ii) a reference level of a spectral signal at 3.15 and 3.19 ppm from a breast of a healthy subject, to determine whether (i) the level of the signal obtained in step a. exceeds the reference level of a healthy subject from step b (ii); (ii) is comparable to that of a subject, known to be at elevated risk of developing breast cancer; or (iii) is elevated to the level of persons known to be carrying a gene mutation.
2 . The method of claim 1 , wherein the spectral signal obtained in step a is obtained using 2D (Two Dimensional) COrelated SpectroscopY (2D COSY).
3 . The method of claim 1 , wherein the spectral signal obtained in step a is obtained from a 1D (One Dimensional) MRS signal.
4 . A system for enabling a determination of a risk of developing breast cancer of a subject by in vivo acquisition of spectral data of a breast tissue of the subject, comprising:
a. a magnetic resonance spectroscopy device to obtain a level of a spectral signal at 3.15 and 3.19 ppm (parts per million), within a breast tissue of the subject, and
b. a comparator for comparing (i) the level of the spectral signal obtained in step a. with (ii) a reference level of a spectral signal at 3.15 and 3.19 ppm from a breast of a healthy subject, to determine whether (i) the level of the signal obtained in step a. exceeds the reference level of a healthy subject from step b (ii), (ii) is comparable to that of a subject known to be at elevated risk, or (ii) is elevated to the level of persons known to be carrying a gene mutation.
5 . The system of claim 4 , wherein the spectral signal is obtained using 2D (Two Dimensional) COrelated SpectroscopY (2D COSY) or by using 1D (One Dimensional) MRS.
6 . The system of claim 4 , wherein the spectral signal obtained in step a is obtained using a 1D MRS signal.
7 . A method enabling a determination of a risk of developing breast cancer of a subject, comprising:
a. Processing spectral data obtained in vivo from a breast tissue of the subject using a magnetic resonance spectroscopy device to obtain a level of a spectral signal at 3.15 and 3.19 ppm (parts per million), and
b. comparing (i) the level of the spectral signal obtained in step a. with (ii) a reference level of a spectral signal at 3.15 and 3.19 ppm from a breast of a healthy subject, to determine whether the level of the signal obtained in step a. (i) exceeds the reference level of a healthy subject from step b (ii); (ii) is comparable to that of a subject known to be at elevated risk; or (iii) is elevated to the level of persons known to be carrying a gene mutation.
8 . The method of claim 7 , wherein the spectral signal obtained in step a is obtained using 2D (Two Dimensional) COrelated Spectroscop Y (2D COSY).
9 . The method of claim 7 , wherein the spectral signal is obtained using a 1D (One Dimensional) MRS signal.
10 . A system for enabling a determination of a risk of developing breast cancer of a subject by in vivo acquisition of spectral data of a breast tissue of a subject, comprising:
a. a processor for processing spectral data obtained in vivo from the breast tissue of the subject using a magnetic resonance spectroscopy device to obtain a level of a spectral signal at 3.15 and 3.19 ppm (parts per million), and
b. a comparator for comparing (i) the level of the spectral signal obtained in step a. with (ii) a reference level of a spectral signal at 3.15 and 3.19 ppm from a breast tissue of a healthy subject, to determine whether the level of the signal obtained in step a. (i) exceeds the reference level of a healthy subject from step (b) (ii), (ii) is comparable to that of a subject known to be at elevated risk, or (iii) is elevated to the level of persons known to be carrying a gene mutation.
11 . The system of claim 10 , wherein the spectral signal obtained in step a is obtained using 2D (Two Dimensional) COrelated SpectroscopY (2D COSY) or by datamining 1D (One Dimensional) MRS.
12 . The system of claim 10 , wherein the spectral signal (obtained in step a) is obtained using data mining of a 1D MRS signal.